CRISPR Therapeutics, Vertex Pharmaceuticals Ink $105M Collaboration Deal
Oct 26, 2015 | a GenomeWeb staff reporter
NEW YORK (GenomeWeb) – CRISPR Therapeutics and Vertex Pharmaceuticals have linked up for a four-year strategic research collaboration to develop new treatments of genetic diseases using CRISPR/Cas9 genome editing.
The partners will evaluate the use of CRISPR/Cas9 in multiple diseases where gene targets have already been established by genetics research, including cystic fibrosis and sickle cell disease. Under the terms of the agreement, the partners will also evaluate an enumerated but undisclosed number of targets. Vertex will provide CRISPR Therapeutics with a $75 million up-front cash payment as well as a $30 million equity investment. CRISPR Therapeutics is also eligible to receive development, regulatory, and sales milestone payments of up to $420 million as well as royalty payments on future sales.
CRISPR Therapeutics will conduct the research, with Vertex covering all related expenses. Vertex holds the option to exclusively license up to six of any gene-based therapies that emerge from the collaboration.
The firms said in a statement that the initial focus of the collaboration will be to try to correct mutations in the cystic fibrosis transmembrane conductance regulator gene.
The collaboration will also focus on treatments for hemoglobinopathies, such as sickle cell disease. For treatments of these diseases, the partners will share all R&D costs equally and CRISPR Therapeutics will lead commercialization activities in the US.
The collaboration also provides Vertex with an observer seat on the CRISPR Therapeutics board of directors.
Basel, Switzerland-based CRISPR Therapeutics was co-founded by CRISPR/Cas9 pioneer Emmanuelle Charpentier and Nobel laureate Craig Mello, among others. The firm has R&D operations based in Cambridge, Massachusetts and corporate offices in London.
DON'T MISS OUT! Come hear the very latest about what is known about and what hope we have for a cure for HSP and PLS. Also, you will love meeting and learning from over one hundred other people with these conditions. Make friends, learn from others about how to cope, the best tools and just have a great time.
When Clinical Trials begin in 2017 it may require as many people as possible for the Clinical Trial to be effective. If you have HSP or PLS, please add your information to our data base so we can keep you informed. We are missing a lot people's email address, so if you just want to add your email address. just enter your name, address and email and we'll add it. That way, we will be able to reach you quickly at a lower cost. Your privacy is very important to us. We will never share any of your information with any individual or company without your permission.
93 cents of every dollar you donate goes into our mission of research and service. 4 cents goes to fundraising and 3 cents goes to data management and general expenses. Our all volunteer Scientific Advisory Board makes sure that we are supporting only the very best research projects on the planet. The Spastic Paraplegia Foundation is an all volunteer run foundation. Our highly skilled staff, Scientific Advisory Board, Medical Advisors, CPA, Attorney, President, Board Members - all of us are working hard every day probono because we strongly believe in this cause. We know a cure is right within reach and we ask you to please join us in reaching by making a tax deductible donation.